T. Rowe Price Associates
DERM icon

T. Rowe Price Associates’s Journey Medical DERM Stock Holding History

T. Rowe Price Associates’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,215
Closed -$53K – 3264
2026
Q1 		$53K Buy
+11,215
New +$87.1K ﹤0.01% 3072

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

T. Rowe Price Associates's DERM Position: Q2 2026 in Review

T. Rowe Price Associates sold out of Journey Medical (DERM) in Q2 2026, closing a stake of 11,215 shares — an estimated $53K sold.

T. Rowe Price Associates first reported a position in DERM in Q1 2026 and held it in 1 quarter. The position peaked at $53K in Q1 2026. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • T. Rowe Price Associates reported no remaining Journey Medical position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 11,215 Journey Medical shares in Q2 2026, an estimated $53K.
  • T. Rowe Price Associates first reported a position in Journey Medical in Q1 2026 and held it in 1 quarter.
  • T. Rowe Price Associates's Journey Medical position peaked at $53K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.